Newbury Pharmaceuticals AB (FRA:P52) Total Liabilities: €4.33 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:P52 Newbury Pharmaceuticals AB FRA:P52
41 GF Score
Price €0.16
GF Value €0.20
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Total Liabilities?

Newbury Pharmaceuticals AB FRA:P52 -10.37% 41 Total Liabilities is €4.33 Mil as of Feb. 2026. GuruFocus rates FRA:P52 with a GF Score™ of 41/100 and a GF Value™ of €0.20. The stock has 6 warning signs investors should review.

Newbury Pharmaceuticals AB's Total Liabilities for the quarter that ended in Feb. 2026 was €4.33 Mil.

Newbury Pharmaceuticals AB's quarterly Total Liabilities increased from Aug. 2025 (€3.10 Mil) to Nov. 2025 (€3.71 Mil) and increased from Nov. 2025 (€3.71 Mil) to Feb. 2026 (€4.33 Mil).

Newbury Pharmaceuticals AB's annual Total Liabilities increased from Aug. 2023 (€1.99 Mil) to Aug. 2024 (€3.40 Mil) but then declined from Aug. 2024 (€3.40 Mil) to Aug. 2025 (€3.10 Mil).

Newbury Pharmaceuticals AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Newbury Pharmaceuticals AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB Total Liabilities Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Total Liabilities
0.43 1.73 1.99 3.40 3.10

Newbury Pharmaceuticals AB Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.81 3.61 3.10 3.71 4.33
FRA:P52
41GF Score
Newbury Pharmaceuticals AB FRA:P52
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newbury Pharmaceuticals AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Newbury Pharmaceuticals AB's Total Liabilities for the fiscal year that ended in Aug. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.767+(0+0.336
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.10

Total Liabilities=Total Assets (A: Aug. 2025 )-Total Equity (A: Aug. 2025 )
=6.938-3.835
=3.10

Newbury Pharmaceuticals AB's Total Liabilities for the quarter that ended in Feb. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.986+(0+0.34
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.33

Total Liabilities=Total Assets (Q: Feb. 2026 )-Total Equity (Q: Feb. 2026 )
=7.271-2.945
=4.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €4.33 Mil mean?
Newbury Pharmaceuticals AB (FRA:P52) has a Total Liabilities of €4.33 Mil as of Feb. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Newbury Pharmaceuticals AB and its competitors.
Is Newbury Pharmaceuticals AB's Total Liabilities too high?
Newbury Pharmaceuticals AB's current Total Liabilities is €4.33 Mil. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Total Liabilities compare to ZTS and UTHR?
Newbury Pharmaceuticals AB's Total Liabilities of €4.33 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Newbury Pharmaceuticals AB and its competitors. Newbury Pharmaceuticals AB's current Total Liabilities is €4.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current Total Liabilities of €4.33 Mil. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current Total Liabilities is €4.33 Mil. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current Total Liabilities is €4.33 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.

Key valuation signals for FRA:P52:

  • Total Liabilities: €4.33 Mil
  • GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newbury Pharmaceuticals AB Business Description

Other Exchanges NEWBRY:Sweden
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score

Get the complete analysis for FRA:P52

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.20
GF Value